USPTO 2015–2025 USPTO PatentsView US Corporation

BeneVir Biopharm, Inc.

USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, recorded in grant years 2017–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Benevir ranks #45,128 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 3 technology areas.

#45,128
of 49,997 US assignees by volume
23rd percentile
by Innovation Score (27.3/100)
38.0
avg claims per patent
-75%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R45128 · US Corporation #45,128 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #45,128/49,997
  • PHOTO-FINISH Belle-V
  • CPC-NARROW A61P · 3 areas
  • INNOV-THIN 27.3/100
  • CLAIMS-DENSE 38.0 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -75% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Belle-V, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Benevir’s 27.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Benevir

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Benevir's Innovation Score is 27.3/100 (23rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Benevir?

Each dot is one of Benevir’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Benevir’s own 38.0 claims/patent is ABOVE the 7.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Benevir vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 4.95.05.055.05.05.1 010203040 Granted patents (volume) Avg claims / patent Belle-V, LLC - 5, 4.8Belle-vBelltec Industries, Inc. - 5, 4.2Belltec IndustriesBendicion, LLC - 5, 1BendicionBendit Technologies Ltd. - 5, 8.6BenditBespoke Bioscience, LLC - 5, 7.6Bespoke BioscienceBestway Oilfield, Inc. - 5, 13.6Bestway OilfieldBetafence USA LLC - 5, 21Betafence USABetter All Around Limited - 5, 7.4Better All AroundBeneVir Biopharm, Inc. - 5, 38Benevir Biopharm
Benevir vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Benevir's grants concentrate

BeneVir Biopharm, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2017. By volume, Benevir sits between Belle-V, LLC and Better All Around Limited.

Who files at BeneVir's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows BeneVir holds 5 patents at rank #45,268, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near BeneVir

By rank, the assignees closest to #45,268 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in BeneVir's primary technology class.

Benevir's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 23rd percentile higher than 23% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2017201820192021 1
USPTO utility patent grants by year · 2017–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
BeneVir Biopharm, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 20.0%
2018 1 20.0%
2019 2 40.0%
2021 1 20.0%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

BeneVir Biopharm, Inc.'s patent record in context - here's where to go next.

  • BeneVir Biopharm, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #45,128 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare BeneVir Biopharm, Inc. against Belle-V, LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 27.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.